Vascular endothelial growth factor receptor-2, (VEGFR-2), is a key element in angiogenesis, the process by which new blood vessels are formed, and is thus an important pharmaceutical target. Here, 3-D quantitative structure-activity relationship (3-D QSAR) were used to build a quantitative screening and pharmacophore model of the VEGFR-2 receptors for design of inhibitors with improved activities. Most of available experimental data information has been used as training set to derive optimized and fully cross-validated eight mono-probe and a multi-probe quantitative models. Notable is the use of 262 molecules, aligned following both structure-based and ligand-based protocols, as external test set confirming the 3-D QSAR models' predictive c...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these ...
International audienceVascular endothelial growth factor receptor-2, (VEGFR-2), is a key element in ...
The growth and metastasis of solid tumors are dependent on angiogenesis. The vascular endothelial gr...
Angiogenesis is defined as the formation of new blood vessels and is a key phenomenon manifested in ...
In this study, binding efficiency of new pyrrolopyrimidine structural analogs against human vascular...
AbstractPharmacophore modeling studies were undertaken for a series of quinoline derivatives as VEGF...
The vascular endothelial growth factor receptor 2 (VEGFR-2) is largely recognized as a potent therap...
Vascular endothelial growth factor (VEGF) is an angiogenic factor involved in tumor growth and metas...
Vascular endothelial growth factor (VEGF) is an angiogenic factor involved in tumor growth and metas...
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays cr...
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these ...
Background and purpose: In this study, the pharmacological activity of 33 compounds of furopyrimidin...
The Vascular Endothelial Growth Factor receptors (VEGF-Rs) play a significant role in tumor developm...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these ...
International audienceVascular endothelial growth factor receptor-2, (VEGFR-2), is a key element in ...
The growth and metastasis of solid tumors are dependent on angiogenesis. The vascular endothelial gr...
Angiogenesis is defined as the formation of new blood vessels and is a key phenomenon manifested in ...
In this study, binding efficiency of new pyrrolopyrimidine structural analogs against human vascular...
AbstractPharmacophore modeling studies were undertaken for a series of quinoline derivatives as VEGF...
The vascular endothelial growth factor receptor 2 (VEGFR-2) is largely recognized as a potent therap...
Vascular endothelial growth factor (VEGF) is an angiogenic factor involved in tumor growth and metas...
Vascular endothelial growth factor (VEGF) is an angiogenic factor involved in tumor growth and metas...
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays cr...
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these ...
Background and purpose: In this study, the pharmacological activity of 33 compounds of furopyrimidin...
The Vascular Endothelial Growth Factor receptors (VEGF-Rs) play a significant role in tumor developm...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) plays a key role on tumor angiogenesis. Inhib...
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these ...